Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 11, 2012, Pages 2036-2042

  Park, Ji Young ^a,b   Jeong, Hyung Jae ^a   Kim, Jang Hoon ^a   Kim, Young Min ^a   Park, Su Jin ^a   Kim, Doman ^b   Park, Ki Hun ^c   Lee, Woo Song ^a   Ryu, Young Bae ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Chonnam National University   (South Korea)

^c Gyeongsang National University   (South Korea)

Author keywords

Alnus japonica; Cysteine protease; Diarylheptanoid; Papain like protease; Severe acute respiratory syndrome

Indexed keywords

ALCOHOL; ALNUS JAPONICA EXTRACT; ALPHA,BETA UNSATURATED CARBONYL; ANTIVIRUS AGENT; CARBONYL DERIVATIVE; CATECHOL; CURCUMIN; CYSTEINE PROTEINASE; GLUCOPYRANOSIDE; HEPTANE DERIVATIVE; HIRSUTANONOL; HIRSUTENONE; OREGONIN; PAPAIN LIKE PROTEINASE; PLANT EXTRACT; PLATYPHYLLENONE; PLATYPHYLLONE; PLATYPHYLLONOL 5 XYLOPYRANOSIDE; PROTEINASE; RUBRANOL; RUBRANOSIDE A; RUBRANOSIDE B; UNCLASSIFIED DRUG; XYLOPYRANOSIDE;

ALDER; ANTIVIRAL ACTIVITY; ARTICLE; DRUG INHIBITION; DRUG ISOLATION; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME REGULATION; IC 50; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; STRUCTURE ACTIVITY RELATION;

ALNUS; ANTIVIRAL AGENTS; CYSTEINE ENDOPEPTIDASES; DIARYLHEPTANOIDS; ESCHERICHIA COLI; PLANT BARK; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS;

EID: 84869221408     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00623     Document Type: Article

References (24)

1. Berger A, Drosten Ch, Doerr HW, Stürmer M, Preiser W. Severe acute respiratory syndrome (SARS)-paradigm of an emerging viral infection. J. Clin. Virol., 29, 13-22 (2004).
2. Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, Rappuoli R. SARS - beginning to understand a new virus. Nat. Rev. Microbiol, 1, 209-218 (2003).
3. Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguière AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Müller S, Rickerts V, Stürmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel Coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med., 348, 1967-1976 (2003).
4. Bartlam M, Yang H, Rao Z. Structural insights into SARS coronavirus proteins. Curr. Opin. Struct. Biol., 15, 664-672 (2005).
5. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, Sun L, Mo L, Ye S, Pang H, Gao GF, Anand K, Bartlam M, Hilgenfeld R, Rao Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U.S.A., 100, 13190-13195 (2003).
6. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science, 300, 1763-1767 (2003).
7. Han YS, Chang GG, Juo CG, Lee HJ, Yeh SH, Hsu JT, Chen X. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome Coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. Biochemistry, 44, 10349-10359 (2005).
8. Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, Baker SC. The papain-like protease of severe acute respiratory syndrome Coronavirus has deubiquitinating activity. J. Virol., 79, 15189-15198 (2005).
9. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YS, Hsu HH, Huang HC, Wu D, Brik A, Liang FS, Lm RS, Fang JM, Chen ST, Liang PH, Wong CH. Small molecules targeting severe acute respiratory syndrome human Coronavirus. Proc. Natl. Acad. Sci. U.S.A., 101, 10012-10017 (2004).
10. Shie JJ, Fang JM, Kuo TH, Kuo CJ, Liang PH, Huang HJ, Wu YT, Jan JT, Cheng YS, Wong CH. Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic α,β-unsaturated esters. Bioorg. Med. Client., 13, 5240-5252 (2005).
11. Regnier T, Sarma D, Hidaka K, Bacha U, Freire E, Hayashi Y, Kiso Y. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors. Bioorg. Med. Chem. Lett., 19, 2722-2727 (2009).
12. pro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorg. Med. Chem. Lett., 20, 1873-1876 (2010).
13. pro inhibition. Bioorg. Med. Chem., 18, 7940-7947 (2010).
14. Chou CY, Chien CH, Han YS, Prebanda MT, Hsieh HP, Turk B, Chang GG, Chen X. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome Coronavirus. Biochem. Pharmacol., 75, 1601-1609 (2008).
15. Ghosh AK, Takayama J, Aubin Y, Ratia K, Chaudhuri R, Baez Y, Sleeman K, Coughlin M, Nichols DB, Mulhearn DC, Prabhakar BS, Baker SC, Johnson ME, Mesecar AD. Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. J. Med. Chem., 52, 5228-5240 (2009).
16. Lai YC, Chen CK, Lin WW, Lee SS. A comprehensive investigation of anti-inflammatory diarylheptanoids from the leaves of Alnus formosana. Phytochemistry, 73, 84-94 (2012).
17. Lee WS, Kim JR, Im KR, Cho KH, Sok DE, Jeong TS. Antioxidant effects of diarylheptanoid derivatives from Alnus japonica on human LDL oxidation. Planta Med., 71, 295-299 (2005).
18. Tung NH, Kwon HJ, Kim JH, Ra JC, Ding Y, Kim JA, Kim YH. Anti-influenza diarylheptanoids from the bark of Alnus japonica. Bioorg. Med. Chem. Lett., 20, 1000-1003 (2010).
19. Sun H, Luo H, Yu C, Sun T, Chen J, Peng S, Qin J, Shen J, Yang Y, Xie Y, Chen K, Wang Y, Shen X, Jiang H. Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS Coronavirus. Protein Expr. Purif, 32, 302-308 (2003).
20. Han YS, Chang GG, Juo CG, Lee HJ, Yeh SH, Hsu J, Chen TX. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome Coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. Biochemistry, 44, 10349-10359 (2005).
21. Grum-Tokars V, Ratia K, Begaye A, Baker SC, Mesecar AD. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery. Virus Res., 133, 63-73 (2008).
22. Ratia K, Saikatendu KS, Santarsiero BD, Barretto N, Baker SC, Stevens RC, Mesecar AD. Severe acute respiratory syndrome Coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc. Natl. Acad. Sci. U.S.A., 103, 5717-5722 (2006).
23. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos., 32, 821-827 (2004).
24. Venkateswarlu S, Ramachandra MS, Subbaraju GV. Synthesis and biological evaluation of polyhydroxycurcuminoids. Bioorg. Med. Chem., 13, 6374-6380 (2005).